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INTRODUCTION
Autologous stem cell transplantation (ASCT), using
hematopoietic progenitor cells derived from either bone
marrow or peripheral blood, allows for the administration of
chemotherapy with a several-fold increase in the drug doses.
The goal of high-dose chemotherapy (HDCT) is to achieve
a higher tumor-cell kill than that achieved with standard-
dose therapy in the hope that it will translate into improve-
ments in long-term disease-free survival (DFS) and overall
survival (OS). In this setting, nonhematopoietic organ toxic-
ities become dose limiting [1]. Improvements in supportive
care have produced a decrease in the morbidity and mortal-
ity associated with HDCT to a current toxic death rate of
less than 5% in centers where large numbers of these proce-
dures are performed [2].
DOSE INTENSITY AND BREAST CANCER
Following observations of in vitro dose response, multi-
ple retrospective analyses have demonstrated a clear correla-
tion between dose intensity of chemotherapy and response
rate and outcome in breast cancer, in both the metastatic [3-
5] and the adjuvant [6,7] setting. Prospective studies of con-
ventional chemotherapy in metastatic breast cancer (MBC)
have demonstrated that decreasing the dose below the stan-
dard range compromises the antitumor effect and palliative
Status of High-Dose Chemotherapy for Breast Cancer: 
A Review
Yago Nieto,1 Richard E. Champlin,2 John R. Wingard,3 James J. Vredenburgh,4 Anthony D. Elias,5
Paul Richardson,5 John Glaspy,6 Roy B. Jones,1 Patrick J. Stiff ,7 Scott I. Bearman,1 Pablo J. Cagnoni,1
Peter A. McSweeney,1 C. Fred LeMaistre,8 Andrew L. Pecora,9 Elizabeth J. Shpall1
1University of Colorado Bone Marrow Transplant Program, Denver, Colorado; 2M.D. Anderson Cancer Center,
Houston, Texas; 3University of Florida Bone Marrow Transplant Program; 4Duke University Bone Marrow Transplant
Program, Durham, North Carolina; 5Dana Farber Cancer Institute, Boston, Massachusetts; 6University of California,
Los Angeles, California; 7Loyola University, Chicago, Illinois; 8South Texas Cancer Institute, San Antonio, Texas;
9Northern New Jersey Cancer Associates, Hackensack, New Jersey
Correspondence and reprint requests: Yago Nieto, MD, University of Colorado Health Sciences Center, B#190,
4200 East Ninth Ave., Denver, CO 80262 (email: yago.nieto@uchsc.edu).
(Received June 10, 2000; accepted June 21, 2000)
ABSTRACT
The purpose of this review is to analyze the current status of high-dose chemotherapy (HDCT) with autologous
stem cell transplantation for patients with breast cancer. Current results from the major prospective phase 2 and
phase 3 trials in metastatic breast cancer (MBC) and high-risk primary breast cancer (HRPBC) are reviewed. Prog-
nostic factors and future research directions are also discussed. The encouraging results of phase 2 trials suggested
a benefit for HDCT in HRPBC and some categories of patients with MBC. Some investigators have argued that
patient selection might have been a critical factor in those studies. Recently reported randomized trials in patients
with chemosensitive MBC have included only small numbers of patients in complete remission and thus have not
adequately addressed the relative value of HDCT versus maintenance standard-dose chemotherapy in this patient
subset. Although initial results of 2 studies have been reported, most randomized phase 3 studies of HDCT in
HRPBC require longer follow-up before definitive conclusions can be made about its efficacy in this setting. We
conclude that the role of HDCT for HRPBC or MBC patients has not yet been fully defined. Longer follow-up of
the ongoing randomized trials is necessary, and their mature results will help clarify this important question. In the
meantime, it is imperative that research continues, to enhance the efficacy of the procedure. This may come
through incorporating more active drugs into HDCT regimens and combining HDCT with novel strategies aimed
at eradication of posttransplantation minimal residual disease. 
KEY WORDS 
Breast cancer • High-dose chemotherapy • Stem cell transplantation
Biology of Blood and Marrow Transplantation 6:476-495 (2000)
© 2000 American Society for Blood and Marrow Transplantation ASBMT
High-Dose Chemotherapy for Breast Cancer
477B B & M T
effects [8]. In contrast, trials that tested minor increases in
dose intensity above the standard dose of adriamycin [9],
paclitaxel [10], or epirubicin [11-15] in MBC have failed to
show a progression-free survival (PFS) or OS beneﬁt.
Similar results have been obtained in the adjuvant set-
ting. A prospective randomized trial of cyclophosphamide,
adriamycin, and fluorouracil (CAF) administered to node-
positive patients in 3 dose-intensity levels showed that the
patients who received the intermediate and high doses of
adriamycin had better DFS and OS than those patients who
received the lowest dose. Although there was no statistically
signiﬁcant difference in outcome between the intermediate
and high doses, a trend toward improvement was noted
[16,17]. A similar trial, comparing 50 to 100 mg/m2 of
epirubicin within the fluorouracil, epirubicin, and
cyclophosphamide (FEC) regimen, showed improved DFS
and OS for the higher-dose arm [18]. In contrast, other
studies have not shown a beneﬁt for increases in the doses of
cyclophosphamide [19,20] or adriamycin [21], with granulo-
cyte colony-stimulating factor (G-CSF) support, as part of
adjuvant treatment.
The use of HDCT with ASCT is based on the hypothe-
sis that major dose escalations within the myeloablative
range are needed to overcome tumor cell resistance and pro-
duce a meaningful clinical improvement. Stem cell support
allows for an increase in the dose well beyond normal bone
marrow tolerance in an attempt to maximally capitalize on
the dose-response curve of certain antineoplastic drugs.
HDCT FOR MBC
Initial Phase 2 Studies
MBC is virtually incurable in patients receiving stan-
dard-dose chemotherapy [22]. Although many patients have
tumors that initially respond, conventional-dose chemo-
therapy becomes progressively less active due to the disease
developing resistance to treatment. Since the incorporation
of adriamycin into the therapeutic armamentarium in the
1970s, there has been virtually no improvement in survival
in all the successive clinical trials of standard-dose chemo-
therapy that have tested multiple combinations and newer
drugs, in some cases with remarkable activity, such as the
taxanes. The disappointing results of the Intergroup Eastern
Cooperative Oncology Group (ECOG) 1193 study illustrate
this concept [23]. This trial compared the use of single-
agent adriamycin, single-agent paclitaxel, or both agents
combined with G-CSF support. The combination of adria-
mycin and paclitaxel improved the response rate but showed
no survival beneﬁt over either drug alone.
The first trials of HDCT for MBC in the mid 1980s
were stimulated by the preclinical studies of Frei and col-
leagues [24,25]. As in other settings where chemotherapy is
used with curative intent, these trials assumed the basic prin-
ciple that minor dose reductions would critically compro-
mise outcome, and thus, only the maximally tolerated doses
(MTDs) of the drugs should be delivered. In vitro data and
previous results of chemotherapy in other diseases, such as
leukemia, supported the use of multidrug combinations over
single agents. Alkylating agents—such as cyclophosphamide,
melphalan, cisplatin, carboplatin, BCNU (carmustine), or
thiotepa—were employed in those early trials of HDCT for
breast cancer, given their activity against the tumor, steep
dose-response effect, non–cross-resistance, and nonoverlap-
ping extramedullary toxicities [24].
The sequential strategies used in testing HDCT for
MBC are summarized in Table 1. The initial trials in refrac-
tory MBC patients produced a higher response rate than
previously reported with standard-dose chemotherapy [26-
29]. Responses were short-lived, however, and had no
demonstrated impact on OS. Results improved when
HDCT was moved up-front as initial therapy for metastatic
disease. Peters et al. [30] at Duke University treated 22
patients with previously untreated MBC (64% of them had
received previous adjuvant chemotherapy) with the Solid
Tumor Autologous Marrow Program (STAMP)-I regimen
(cyclophosphamide 5625 mg/m2, cisplatin 165 mg/m2, and
BCNU 600 mg/m2). Three patients (14%) were disease-free
at the time of the initial publication and still had no evi-
dence of relapse in the recently updated results of this trial,
with a follow-up of more than 10 years [31].
In a subsequent step, HDCT was used as immediate con-
solidation after dose-intense adriamycin-based induction
chemotherapy, which was administered to maximally cyto-
reduce the tumor before HDCT. Phase 2 trials testing this
strategy, using STAMP-I or other high-dose regimens, such
as STAMP-V (cyclophosphamide 6000 mg/m2, thiotepa
500 mg/m2, and carboplatin 800 mg/m2) or CT (cyclophos-
phamide 7500 mg/m2 and thiotepa 675 mg/m2), consistently
Table 1. Sequential Strategies of High-Dose Chemotherapy for Metastatic Breast Cancer*
Transplantation  DFS of 
No. of Median Follow-Up Patients Transplantation 
Strategy Regimen Patients From HDCT, mo in CR, % DFS Rate, % Patients in CR, % Reference
Refractory disease STAMP-I 23 — 0 0 NA [26]
STAMP-V 16 — 0 0 NA [27]
Up-front therapy STAMP-I 22 18 0 14 NA [30]
for untreated MBC
Consolidation STAMP-I 245 67 25 16 28 [32]
after induction Cy/TT 100 62 28 11 31 [36]
STAMP-V 62 50 19 21 31 [34]
*HDCT indicates high-dose chemotherapy; CR, complete remission; DFS, disease-free survival; STAMP-I, cyclophosphamide, cisplatin, and
BCNU; NA, not applicable; STAMP-V, cyclophosphamide, thiotepa, and carboplatin; MBC, metastatic breast cancer; Cy/TT, cyclophosphamide
and thiotepa.
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showed a long-term DFS rate of 15% to 25% (Table 2) [32-
36]. Because HDCT was shown to be most effective at a time
of minimal tumor burden, potent induction regimens, such as
AFM (adriamycin, ﬂuorouracil, and methotrexate) as reported
by Jones et al. [37], were designed to provide substantial
cytoreduction before HDCT. Local treatment with surgery
or radiotherapy (RT) was added posttransplantation to sites of
prior bulky disease. Recently reported data conﬁrm the bene-
ﬁt of RT consolidation after HDCT for MBC [38].
In parallel to these advances, the introduction of myeloid
growth factors posttransplantation, peripheral blood pro-
genitor cells (PBPCs) in place of bone marrow, and other
improvements in supportive care reduced the treatment-
related mortality rate from the initial 15% to 20% rate to the
current 2% to 4% expected in experienced transplantation
units [2].
The 15% to 20% fraction of patients with chemosensi-
tive MBC rendered long-term free of disease by HDCT
appeared to be substantially higher than the expected long-
term DFS of 0% to 3% using conventional chemotherapy
[22,39,40]. These encouraging phase 2 data, summarized in
Table 2, generated great enthusiasm among physicians and
patients for the use of HDCT. The rapid transfer of stem
cell transplantation technology from the academic environ-
ment to community hospitals resulted in an explosive
growth in the number of breast cancer patients receiving
HDCT, despite the lack of results of randomized studies
demonstrating that this approach should be the standard of
care. From 1992 to 1999, breast cancer was the most com-
mon malignancy reported to the American Blood and Mar-
row Transplant Registry (ABMTR) for which HDCT and
ASCT were administered [2].
Detractors of HDCT have argued that the promising
results may be explained by patient selection (younger age,
better performance status), extensive staging bias, and the
requirement of proven chemosensitivity [41,42]. This ongo-
ing controversy clearly underscores the need for mature
data from prospective, well-designed, and adequately sized
randomized phase 3 trials.
On the other hand, there is a pressing need to improve
HDCT for breast cancer. It would appear unlikely that ﬁrst-
generation high-dose regimens developed 15 years ago, such
as STAMP-I or STAMP-V, are the optimal stem-cell sup-
ported high-dose combinations. While current randomized
trials, initiated a decade ago, are testing such ﬁrst-genera-
tion HDCT regimens, several new strategies are being
actively pursued. These include the development of new
HDCT regimens, tandem or multiple transplantations, and
combination of HDCT plus treatments with novel mecha-
nisms of action targeting posttransplantation minimal resid-
ual disease.
Which MBC Patients Are Most Likely to Benefit
From HDCT?
Although the results from phase 2 trials of HDCT in
MBC were encouraging, it became clear that the majority of
MBC patients still relapsed after HDCT. Several retrospec-
tive analyses have identiﬁed favorable and unfavorable prog-
nostic factors for outcome in this patient population. Dun-
phy et al. [43] reported that metastases in liver or soft tissues
and prior chemotherapy were independent adverse predic-
tors of outcome in their series of 80 patients treated at the
M.D. Anderson Cancer Center with tandem cycles of
DICEP (cyclophosphamide, etoposide, and cisplatin). Ayash
et al. [44] observed that 1 site of disease and attainment of a
complete remission (CR) to induction chemotherapy were
independent favorable predictors of DFS in their series of
80 patients treated with STAMP-V at Dana Farber Cancer
Table 2. Overall Results From Major Phase 2 Studies of High-Dose Chemotherapy for Breast Cancer*
Median Follow-Up DFS Rate, %
Setting and No. of Patients High-Dose Regimen From HDCT, mo All Patients CR at Transplantation Reference 
4-9 nodes
54 STAMP-I 32 80 — [107]
≥10 nodes
85 STAMP-I 60 71 — [104]
67 HDST 48 57 — [105]
Inflammatory carcinoma
46 STAMP-V 27 68 — [113]
30 STAMP-I 23 73 — [114]
17 Cy/mitox/mel 36 59 — [115]
22 CAVP/CCVP 46 45 — [116]
47 Several 27 58 — [117]
Metastatic chemosensitive
245 STAMP-I 67 16 28 [33]
100 Cy/TT 62 11 31 [36]
62 STAMP-V 50 21 31 [34]
Metastatic NED
40 STAMP-I 49 55 — [46]
20 Cy/mitox/carbo 28 55 — [47]
*HDCT indicates high-dose chemotherapy; DFS, disease-free survival; CR, complete remission; STAMP-I, cyclophosphamide, cisplatin, and
BCNU; HDST, high-dose sequential therapy using cyclophosphamide, vincristine, methotrexate, and melphalan; STAMP-V, cyclophosphamide,
thiotepa, and carboplatin; Cy, cyclophosphamide; mitox, mitoxantrone; mel, melphalan; CAVP, cyclophosphamide, adriamycin, and VP-16 (etopo-
side); CCVP, cyclophosphamide, cisplatin, and VP-16; TT, thiotepa; NED, no evidence of disease; carbo, carboplatin.
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Institute. Doroshow et al. [45] reported that patients trans-
planted in CR, without liver metastases, with less prior
chemotherapy, and with fewer metastatic sites had improved
outcome in their series of 104 patients from City of Hope.
Rizzieri et al. [46] analyzed a series of 299 MBC patients
from Duke University who responded to AFM and then
received STAMP-I and observed that visceral metastases,
prior exposure to adjuvant chemotherapy, shorter disease-
free interval from initial diagnosis to metastatic recurrence,
and hormone receptor negativity were adverse predictors of
long-term DFS. Overexpression of the Her-2/neu oncogene
[45], or detection of high serum levels of its extracellular
domain [47], has been identiﬁed as an adverse predictor of
outcome in MBC patients after HDCT.
Antman et al. [2] reported the results of HDCT, using a
variety of regimens, in 2030 MBC patients registered at the
ABMTR. Disease status at transplantation was a critical pre-
dictor: those patients transplanted in CR presented a 32%
3-year DFS rate, compared with 13% for those transplanted
in partial remission (PR) and 7% for those with chemore-
fractory disease.
A prognostic analysis of MBC patients registered at the
ABMTR was recently reported by Rowlings et al. [48]. The
following adverse predictors were identified: (1) an initial
disease-free interval after adjuvant therapy of ≤18 months,
with a relative risk (RR) of 1.99; (2) a PR (versus a CR), to
pre-HDCT induction chemotherapy (RR = 1.65); (3) central
nervous system (RR = 1.56) or liver (RR = 1.47) metastases;
(4) 3 or more sites of disease (RR = 1.32); (5) prior exposure
to adjuvant chemotherapy (RR = 1.31); (6) negative hormone
receptors (RR = 1.31); (7) Karnofsky performance score
<90%; and (8) age >45 years (RR = 1.17). Patients with MBC
and none of those risk factors presented a 43% 3-year DFS,
compared with 4% for those patients with ≥3 risk factors.
Thus, we are currently able to identify patients with
poor prognostic features who are less likely to beneﬁt from
the first-generation HDCT regimens. Newer high-dose
regimens or alternative HDCT-based strategies are being
explored for these patients.
The hypothesis that MBC patients with a good progno-
sis might attain major benefit from HDCT early in the
course of their disease was prospectively tested at the Uni-
versity of Colorado [49]. A phase 2 study of 4 cycles of adri-
amycin-based induction therapy followed by HDCT with
STAMP-I was conducted in 40 consecutive MBC patients
with no evidence of disease (NED). The NED status was
deﬁned as 1 or more sites of macroscopic tumor that could
be resected en bloc or encompassed within a single RT ﬁeld
or was <5% of bone marrow involvement. Although most
patients had received previous adjuvant chemotherapy, no
prior chemotherapy was allowed for metastatic disease. At a
median follow-up of 49 months, the DFS and OS rates were
55% and 65%, respectively, with median DFS and OS times
of 43 and 77 months, respectively (Figure 1). In the sub-
group of patients with a single metastatic site, 68% of them
remained alive with no evidence of recurrence.
Similar results were reported by Abraham et al. [50]
using high-dose mitoxantrone, cyclophosphamide, and car-
boplatin in 20 patients with isolated supraclavicular lymph
node metastases, with a 55% DFS rate at a median follow-
up of 28 months.
These results advocate for closer follow-up after adju-
vant treatment for early detection of relapses and for the use
of early HDCT in MBC with minimal disease. Randomized
trials in this subset of MBC patients should be considered in
the future.
Are Current HDCT Regimens Better Than
Standard-Dose Chemotherapy for MBC? 
Peters et al. [51] reported the preliminary results of a ran-
domized trial comparing immediate versus delayed use of
HDCT with STAMP-I in hormone-refractory MBC patients
in CR following AFM. Of the 423 enrolled patients, 113
(27%) achieved a CR, and 100 patients were randomized to
immediate transplantation (n = 49) or observation (n = 51).
Patients in PR were offered HDCT off study. Patients in the
observation arm were offered HDCT at the time of relapse
(Figure 2). At median follow-up of 6.3 years, median DFS
Figure 1. Relapse-free survival (RFS) and overall survival (OS) of metastatic breast cancer patients with no evidence of disease (n = 40). HDC indi-
cates high-dose chemotherapy. From the University of Colorado Bone Marrow Transplant Program.
Y. Nieto et al.
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times are 9.7 months for the immediate transplantation arm
and 3.8 months for the observation arm (P = .006), with 6-
year DFS rates of 25% and 10%, respectively. Median OS
times for the immediate transplantation and observation arms
are 2.34 and 3.57 years, respectively (P = .32), with 6-year OS
rates of 33% and 38%, respectively (J.J. Vredenburgh, per-
sonal communication). Although this trial was not designed
to directly compare HDCT and standard-dose therapy, its
results suggest that HDCT may improve DFS and OS in
MBC patients in CR after standard-dose chemotherapy.
The results of the Philadelphia/ECOG PBT-1 random-
ized trial comparing HDCT with STAMP-V to maintenance
chemotherapy with cyclophosphamide, methotrexate, and 5-
ﬂuorouracil (CMF) in chemoresponsive MBC patients were
reported at the 1999 American Society of Clinical Oncology
(ASCO) Meeting and have been recently published [52].
Stadtmauer et al. [52] initially enrolled 553 MBC patients to
receive induction chemotherapy with CAF (n = 507) or
CMF (n = 46). Of those, 303 patients (54%) achieved a PR
(n = 247) or a CR (n = 56). Of the 303 responding patients,
199 were randomized, of whom 110 were allocated to
STAMP-V and 89 to maintenance CMF for 18 months or
until disease progression (Figure 3). After considering 15 of
those patients ineligible after randomization, 184 were actu-
ally treated in study, 101 in the HDCT arm and 83 in the
CMF arm, 139 in PR and 45 in CR. Both study arms were
well balanced for estrogen receptor (ER) expression (47%
and 46%, respectively), but the HDCT arm had more
patients with prior exposure to adjuvant chemotherapy (55%
versus 46%) and with visceral disease (57% versus 48%). An
intent-to-treat analysis at a median follow-up of 31 months
showed no statistically significant differences between the
STAMP-V and the CMF arms in DFS (6% and 12%,
respectively), OS (32% and 38%, respectively), or time to
progression (9.6 and 9 months, respectively). This trial was
initially designed to have an 85% power to detect a doubling
in median OS in the HDCT arm, expecting a 10% ineligi-
bility rate and a 10% noncompliance rate. Its actual drop-out
rates were 34% before and 11% after randomization. Only
45 patients in CR were randomized and treated, conferring
only a 20% power to detect a 20% difference in OS between
both arms. As has been pointed out [53], the Philadelphia
trial cannot exclude a role of STAMP-V for patients in CR.
The toxicity in the transplantation arm was, as expected,
higher than in the CMF arm, but only 1 of the 101 trans-
plantation patients died of treatment-related toxicity. Sur-
prisingly, in the group of patients in PR (n = 139), the PR-
to-CR conversion rate was higher in the maintenance CMF
arm (9%) than in the STAMP-V arm (6%). The low conver-
sion rate from PR to CR in the transplantation arm of this
trial is quite different than the vast majority of phase 2
HDCT trials, where PR-to-CR conversion rates of 20% to
60% are typically reported [32-36].
Data from the French Programme d’Étude de la Greffe
Autologue dans les Cancers du Stein (PEGASE)-04 ran-
domized study were also reported at the 1999 ASCO Meet-
Figure 3. Philadelphia/Eastern Cooperative Oncology Group randomized study in metastatic breast cancer patients with partial response (PR) or
complete response (CR). PFS indicates progression-free survival; CAF; cyclophosphamide, adriamycin, and 5-fluorouracil; CMF, cyclophos-
phamide, methotrexate, and 5-ﬂuorouracil; SD, stable disease; PD, progressive disease; STAMP-V, high-dose cyclophosphamide, thiotepa, and car-
boplatin; OS, overall survival; DFS, disease-free survival; NS, not signiﬁcant.
Figure 2. Randomized Duke University study on metastatic breast cancer patients in complete remission (CR). AFM indicates adriamycin, 5-ﬂuo-
rouracil, and methotrexate; STAMP-I, high-dose cyclophosphamide, cisplatin, and BCNU; DFS, disease-free survival; OS, overall survival.
→ →
→
→
→
→
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Figure 4. French Programme d’Étude de la Greffe Autologue dans les Cancers du Sein (PEGASE 04) randomized study in metastatic breast cancer
patients with partial response (PR) or complete response (CR). PFS indicates progression-free survival; OS, overall survival; CT, chemotherapy;
CMM, high-dose cyclophosphamide, mitoxantrone, and melphalan; SD, stable disease; PD, progressive disease.
ing. Lotz et al. [54] randomized 61 MBC patients in com-
plete or partieal response after 4 to 6 cycles of conventional-
dose anthracycline-based chemotherapy to additional cycles
of the same regimen or to HDCT with cyclophosphamide,
mitoxantrone, and melphalan (Figure 4). Of those patients,
13 were in CR and 48 in PR before randomization. The
groups were well balanced except for lung metastases (15 in
the HDCT arm and 4 in the control arm) and central ner-
vous system disease (2 in the HDCT arm and 0 in the con-
trol arm). No toxic deaths were seen in either arm. Median
PFS was signiﬁcantly longer in the HDCT arm than in the
control arm (26.9 and 15.7 months, respectively) (P = .04).
The relapse rate was almost twice as high in the control arm
as in the transplantation arm (52% and 27%, respectively),
although this difference was not statistically signiﬁcant (P =
.18). Median OS times were 36.1 and 15.7 months in the
HDCT and control arms, respectively (P = .08). Although
this trial suggested a beneﬁt from HDCT, the small sample
size limited its ability to detect potential statistically signiﬁ-
cant differences.
A small randomized trial in patients with hormone-
refractory MBC conﬁned to the bones was conducted by the
Duke University Bone Marrow Transplant Program and
recently reported at the 2000 ASCO Meeting (Figure 5)
[55]. Study eligibility required no prior chemotherapy for
metastatic disease and either ER-negative or -positive
tumors only after failure of at least 1 hormonal treatment. A
total of 85 patients received 4 cycles of AFM, and 69 who
did not progress while receiving AFM were randomized to
immediate HDCT with STAMP-I followed by RT of all
bony metastases (n = 35) or to RT and observation with
HDCT at the time of progression (n = 34). At median fol-
low-up of 4.9 years, all 34 patients in the observation arm
have progressed, and 27 of them underwent salvage trans-
plantation. Although the median PFS times in the observa-
tion arm (1.24 years) and the immediate transplantation arm
(1 year) were similar, the PFS curve was statistically superior
in the immediate transplantation arm (P = .001). The PFS
rates in the immediate transplantation arm and in the obser-
vation arm after salvage transplantation were 17% and 9%,
respectively. The overall PFS rate for all patients receiving
HDCT (either immediately or upon progression) was 13%.
The OS rate was 28% in the immediate transplantation
arm, 22% in the observation arm, and an overall 23% for all
transplanted patients. The treatment-related mortality rate
for all transplanted patients was high, at 9.7% (6/62).
In summary, currently available results from randomized
trials in MBC reported to date are contradictory. It is note-
worthy that both the Philadelphia and the French trials,
which addressed the value of consolidation with HDCT
versus standard chemotherapy in chemosensitive patients,
were clearly undersized as to the number of patients ran-
→
→
→→
→
→
Figure 5. Duke University randomized study in bone-only metastatic breast cancer. PFS indicates progression-free survival; OS, overall survival;
AFM, adriamycin, 5-ﬂuorouracil, and methotrexate; PD, progressive disease; SD, stable disease; STAMP-I, high-dose cyclophosphamide, cisplatin,
and BCNU; xRT, radiotherapy; NS, not signiﬁcant.
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domized in CR. This fact seems critical to interpreting their
results, because patients in CR are the subset of MBC
patients who appear to beneﬁt most from HDCT.
In addition to the prospective randomized trials dis-
cussed above, a retrospective comparison recently per-
formed by Berry et al. [56] illustrates the importance of
long-term follow-up in detecting real differences. These
authors compared survival of 635 patients enrolled in Can-
cer and Leukemia Group B (CALGB) trials of standard-
dose chemotherapy and 441 patients treated with a variety
of HDCT regimens who were registered at the ABMTR.
This analysis was restricted to patients younger than 65 who
had responded to a single chemotherapy regimen in the
metastatic setting, with patient groups being matched for
known prognostic factors. Similar OS rates were observed
during the ﬁrst 2 years after treatment, but a signiﬁcant dif-
ference in favor of HDCT emerged thereafter. The esti-
mated 3-year and 5-year OS rates in the HDCT group
(37% and 22%, respectively) were signiﬁcantly superior to
those in the standard-dose group (27% and 13%, respec-
tively, P = .01). In addition to the large drop-out rate of the
prospective Philadelphia/ECOG trial, the observations
made by Berry et al. cast serious doubts about its power to
detect real differences, as it was reported with a median fol-
low-up of about 3 years.
There are no other randomized trials in MBC currently
open in the United States, but several randomized studies
are underway in Europe and may help clarify this issue
(Table 3).
New HDCT Regimens for MBC
A critical review of the ﬁrst generation of high-dose reg-
imens shows that there is ample room for improvement.
Although cisplatin and carboplatin are active drugs in ﬁrst-
line treatment for breast cancer [57,58], they are only esca-
lated 2-fold above conventional chemotherapy in the
STAMP-I and STAMP-V regimens, respectively. Both regi-
mens also include cyclophosphamide, at doses from 5625 to
6000 mg/m2, administered over 3 (STAMP-I) or 5
(STAMP-V) days. Two recent randomized studies con-
ducted by the National Surgical Adjuvant Breast and Bowel
Project tested dose escalations of cyclophosphamide, com-
bined with adriamycin, in the adjuvant treatment of node-
positive patients [19,20]. No improvement in DFS or OS
was observed from up to 4-fold increases in the dose inten-
sity of cyclophosphamide (2400 mg/m2 every 3 weeks) or its
total dose (9600 mg/m2 over 4 cycles). The failure of such
substantial dose increments of cyclophosphamide to
improve outcome raises serious concerns about its inclusion
in high-dose regimens for breast cancer. A possible explana-
tion for why cyclophosphamide does not show an in vivo
dose-response effect, in contrast to the in vitro observations
using 4-hydroxy-cyclophosphamide, stems from its pharma-
cological properties. Cyclophosphamide is a prodrug that
requires hepatic activation to 4-hydroxy-cyclophosphamide,
a P450-mediated metabolic step that is subject to saturation
and multiple drug–drug interactions [59], such as inhibition
by high-dose thiotepa when both drugs are given concur-
rently as a continuous infusion, as in STAMP-V [60]. Con-
sequently, this activation step has a high interpatient [61]
and intrapatient [62] variability. Busse et al. [63] studied the
intrapatient changes in the metabolic pathways of
cyclophosphamide and its metabolites when given at stan-
dard and high doses, and they observed that at high doses,
the inactivating reactions significantly increased and the
bioactivation of cyclophosphamide was reduced compared
with conventional doses.
Current research efforts are testing high-dose combina-
tions using other, more potent drugs. Although they are not
alkylating agents, a dose-response effect has been shown
with doxorubicin [64], paclitaxel [65-67], and docetaxel [68-
70], the 3 most active agents in breast cancer. Although the
concern about doxorubicin’s potential for cardiotoxicity has
prevented its inclusion in most HDCT regimens, Doroshow
Table 3. Ongoing Randomized Trials in Metastatic Breast Cancer*
Trial (Principal Size of 
Investigator) Target Population Target Population Control Arm High-Dose Arm Study Status
France, PEGASE 03 Untreated patients 180 FEC  4 FEC  4→Cy/TT Accrual closed (5/00); 
(P. Biron) planned analysis: 12/00
Germany, GEBDIS PR/CR after A-Txt  3 350 Observation  ICE→ ICE→Cy/TT Accruing
(L. Kanz) Cy/TT (at relapse)
Canada, NCIC PR/CR after taxane- or 300 Maintenance chemo/ Cy/mitox/carbo Accruing
(M. Crump) anthracycline-based Rx hormonal Rx
European, EBCDIS Untreated patients 264 A-Txt  4→CMF  4 A-Txt  4→ Accruing
(J. Crown) ICE →Cy/TT
Italy, GITMO PR/CR after E-Txt 240 Standard-dose ICE ICE→TT/mel Accruing
(G. Rosti)
Belgium Stage III (T4N2) or IV, 400 enrolled, Txt  1→EC  4 Txt  1→(mitox/mel) Accruing
(M. Piccart) in PR/CR after Txt  3 150 randomized  2
*High-dose regimens are presented in italic. PEGASE indicates Programme d’Étude de la Greffe Autologue dans les Cancers du Sein; FEC, ﬂu-
orouracil, epirubicin, and cyclophosphamide; Cy, cyclophosphamide; TT, thiotepa; GEBDIS, German Breast Cancer Dose Intensity Study; PR,
partial remission; CR, complete remission; A-Txt, adriamycin and taxotere; ICE, ifosfamide, carboplatin, and etoposide; NCIC, National Cancer
Institute of Canada; mitox, mitoxantrone; carbo, carboplatin; EBCDIS, European Breast Cancer Dose Intensity Study; CMF, cyclophosphamide,
methotrexate, and 5-ﬂuorouracil; GITMO, Gruppo Italiano per il Trapianto di Midollo Osseo; E-Txt, epirubicin and taxotere; mel, melphalan;
Txt, taxotere; EC, epirubicin and cyclophosphamide.
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et al. [71] have shown the feasibility and acceptable cardiac
tolerance of high-dose doxorubicin (165 mg/m2) in a 96-
hour continuous infusion, combined with etoposide and
cyclophosphamide.
Myelosuppression is dose limiting when paclitaxel [72]
and docetaxel [73,74] are given at conventional doses. In a
phase 1 trial using ASCT, the MTD of paclitaxel infused over
24 hours, in combination with fixed doses of cyclophos-
phamide and cisplatin, was established at 775 mg/m2 [75].
This dose of paclitaxel is around 3-fold higher than its stan-
dard MTD in 24-hour infusions [76-78]. Paclitaxel has been
subsequently incorporated into other HDCT regimens as
either a single cycle [79,80] or multiple cycles [81,82].
Docetaxel is currently considered by many authors as
the most active drug for breast cancer, either as first-line
therapy [83] or for anthracycline-resistant disease [84,85]. In
a randomized study in MBC patients, the response rate
attained with docetaxel was significantly higher than with
doxorubicin, with both drugs being given at their highest
feasible doses without G-CSF support (100 and 75 mg/m2,
respectively) [86]. A phase 1 trial of stem cell–supported
docetaxel in combination with melphalan and carboplatin in
patients with chemorefractory and heavily pretreated disease
is currently underway at the University of Colorado [87].
This trial has established the MTD of docetaxel at
450 mg/m2, which is a 4.5-fold increment over its standard
dose. Initial evaluation of activity in patients with measur-
able disease shows a high level of activity in this population
with resistant breast cancer (100% RR with 44% CR rate).
Tandem or Multiple Transplantations for MBC
Another hypothesis under evaluation speculates that
more than 1 cycle of HDCT may be needed to eradicate
metastatic disease. Dunphy et al. [88] used 2 cycles of non-
myeloablative dose-intense DICEP, with 25% DFS at 2
years, which appeared comparable to the outcome after a sin-
gle cycle of myeloablative HDCT. Rapid delivery of multiple
cycles of stem cell–supported dose-intense nonmyeloablative
chemotherapy has been shown to be feasible [89,90].
Several authors have investigated the delivery of tandem
cycles of myeloablative HDCT with ASCT after both cycles
[91-93]. The value of a second cycle of the same regimen
remains unclear, because the PR-to-CR conversion rate
appears to decrease substantially from the ﬁrst to the second
cycle of HDCT [93].
Other groups have tested the sequential use of different
non–cross-resistant combinations. Ayash et al. [94] treated
chemosensitive MBC patients with melphalan followed,
within a median of 35 days, by STAMP-V. At a median fol-
low-up of 16 months after the second transplantation, their
34% DFS rate appeared similar to results of a single HDCT
treatment. Preliminary results were reported by Bitran et al.
[95] using the reverse sequence of cyclophosphamide-
thiotepa followed by melphalan, with a longer median inter-
cycle interval of 105 days. The DFS rate was 56% at a
median follow-up of 25 months from the ﬁrst transplanta-
tion. Whether the results of these 2 studies are signiﬁcantly
different is unclear, given their short follow-up and the
overlapping ranges of DFS rates.
More recent trials have incorporated new drugs to this
strategy of sequential non–cross-resistant HDCT cycles.
Vahdat et al. [96] at Columbia University treated 57
chemosensitive MBC patients with 3 separate HDCT cycles
using sequential paclitaxel, melphalan, and STAMP-V, with
58% DFS rate at follow-up of 18 months. Elias et al. [82] at
the Dana Farber Cancer Institute treated 58 patients with
MBC who had responded to 2 prior cycles of single-agent
adriamycin. STAMP-V was preceded (n = 32) or followed
(n = 26) by high-dose melphalan-paclitaxel. The short-term
results reported by these authors—a 2-year DFS rate of
60%—appeared better than those previously observed in a
similar population treated with a single cycle of STAMP-V
at the same institution.
However, other authors have reported less promising
results with multicycle HDCT. Hu et al. [97] at Stanford
University treated 55 MBC patients with 4 cycles of varying
combinations of mitoxantrone, paclitaxel, thiotepa, and
cyclophosphamide, with ASCT. The actuarial 3-year DFS
rate (15%) did not appear different from that observed in 55
contemporaneous MBC patients treated with a single cycle
of STAMP-I (19%).
In parallel with these inconclusive clinical trials, Teicher
et al. [98] described the phenomenon of acute in vivo resis-
tance after HDCT, after treating tumor-bearing mice with
different sequences of several drugs at high doses. Tumors
became chemoresistant after the first treatment in an
inversely proportional fashion to the length of the interval
between treatments. Recent in vitro experiments performed
by Frei et al. [99] also suggest that the speciﬁc sequence of
alkylators used may have a substantial inﬂuence on response.
These authors have shown that initial treatment with high-
dose melphalan appears to generate cross-resistance to sub-
sequent alkylators by increasing tumor-cell concentrations
of glutathione and glutathione-S-transferase-.
HDCT FOR HIGH-RISK PRIMARY BREAST CANCER 
Phase 2 Studies in Node-Positive Patients
Most patients with high-risk primary breast cancer
(HRPBC), deﬁned by extensive axillary node involvement or
inflammatory carcinoma (inflammatory breast cancer),
relapse after surgery and conventional-dose adjuvant
chemotherapy [100,101]. A retrospective analysis by
Hryniuk and Levine [102] suggests that dose intensity may
have a greater impact on survival in the adjuvant setting
than in patients with metastatic disease. However, most
prospective trials have failed to show an improved outcome
from minor dose escalations, as previously detailed. The
most signiﬁcant progress in this ﬁeld of conventional adju-
vant chemotherapy in the last decade has come from a very
large intergroup randomized trial that tested the addition of
4 cycles of paclitaxel to adriamycin-cyclophosphamide in
node-positive patients [21]. The preliminary analysis of this
trial at early follow-up of 18 months showed that the addi-
tion of paclitaxel resulted in very modest, but statistically
signiﬁcant, absolute improvements in the DFS and OS rates
of 4% and 2%, respectively (with 22% and 26% relative
decreases in relapse rate and death rates, respectively).
Future updates of this trial are necessary to adequately assess
the real impact of this approach.
Peters et al. [103] at Duke University conducted the ﬁrst
phase 2 trial of HDCT with STAMP-I in patients with 10
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or more involved axillary nodes. At a median follow-up of 5
years, 71% of 85 evaluable patients remained free of disease
[104]. At the National Tumor Institute in Milan, Gianni et
al. [105] used a sequential high-dose single-agent approach
with ASCT in this patient population. At a median follow-
up of 4 years, the DFS rate was 57%. In retrospect, this
DFS rate appeared to be significantly higher than that
observed in the group of patients with ≥10 involved nodes
who received the most effective of 2 adriamycin-based stan-
dard-dose regimens that were compared in a different ran-
domized trial conducted at the same institution using the
same selection criteria and pretreatment staging as in
Gianni’s HDCT study [106].
Several investigators have tested HDCT for patients
with 4 to 9 involved nodes, whose long-term DFS ranges
from 45% to 76% with standard adjuvant treatment. Bear-
man et al. [107] conducted a pilot trial in which 54 patients
received 4 cycles of standard-dose chemotherapy with adri-
amycin-cyclophosphamide, followed by HDCT using
STAMP-I. In an intent-to-treat analysis, a DFS rate of 71%
was seen at a median follow-up of 31 months. These results
have been reproduced by other groups [108,109]. The
ongoing intergroup Southwestern Oncology Group
(SWOG) 9623 phase 3 trial is randomizing patients to
receive either 4 cycles of adriamycin-cyclophosphamide fol-
lowed by HDCT with STAMP-I or STAMP-V or a dose-
dense G-CSF–supported sequential combination of adri-
amycin, paclitaxel, and cyclophosphamide, designed at
Memorial Sloan Kettering [110]. This trial, which initially
targeted patients with 4 to 9 positive nodes, has been
recently amended to include patients with ≥10 or more
involved nodes.
Inflammatory Breast Cancer 
Patients who present with inflammatory breast cancer
(IBC) experience a very aggressive evolution of this disease,
with a 5-year DFS rate of approximately 30% following
multimodal therapy with doxorubicin-based neoadjuvant
chemotherapy, surgery, adjuvant chemotherapy, and loco-
regional RT [111,112]. In recent phase 2 trials at the Dana
Farber Cancer Institute [113] and the University of Col-
orado Bone Marrow Transplant Program [114], HDCT was
incorporated in varying schedules into a multimodal
approach targeting IBC patients. These studies included
neoadjuvant adriamycin-containing chemotherapy followed
in the Dana Farber study by STAMP-V and posttransplan-
tation mastectomy and in the Colorado trial by pretrans-
plantation mastectomy and STAMP-I. In both studies, RT
and tamoxifen for ER-positive patients were subsequently
delivered. In intent-to-treat analyses, the reported DFS
rates were 64% and 70% at 27 and 19 months from HDCT,
respectively (Figure 6).
Viens et al. [115] treated 17 consecutive IBC patients
with high-dose cyclophosphamide, mitoxantrone, and mel-
phalan with a 59% DFS rate at median follow-up of 36
months. In the series of IBC patients treated at City of
Hope [116] and Washington University [117], using varying
schedules and HDCT regimens, the relapse-free survival
(RFS) rates at median follow-ups of 46 and 30 months were
50% and 59.6%, respectively.
Overall, the promising results of these phase 2 studies
suggest a beneﬁt from the inclusion of HDCT in the multi-
disciplinary management of patients with IBC. Randomized
trials will be necessary to evaluate the potential beneﬁts of
such strategy.
Figure 6. Relapse-free survival curves of the trials of high-dose chemotherapy (HDCT) for high-risk primary breast cancer conducted at the Uni-
versity of Colorado Bone Marrow Transplant Program. Censored patients are indicated by H17009 (≥10 positive nodes, n = 143),  (4-9 positive nodes,
n = 58), or + (inﬂammatory carcinoma, n = 30).
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Predictive Factors for Relapse After HDCT for
HRPBC
Somlo et al. [116] analyzed 114 patients treated with 2
different HDCT regimens at City of Hope National Med-
ical Center and followed for a median of 46 months (range,
23-93 months). These authors observed that the risk of
relapse was lower for patients with PR-positive tumors and
higher for patients with IBC, and that OS was better in
patients with tumors that were PR- or ER-positive and
worse in high-grade tumors. Of all those, PR positivity was
an independent favorable predictor of RFS and OS.
A total of 176 patients treated at the University of Col-
orado with STAMP-I and followed for a median of 45 months
(range, 12-84 months) were analyzed for potential adverse
predictive factors [118]. Tumor size, tumor grade, clinical
IBC, ER/PR negativity, and nodal ratio (number of positive
nodes/number of sampled nodes) were associated with relapse.
Nodal ratio, tumor size, and ER/PR status had independent
value and formed the basis for the following scoring system:
score = (nodal ratio  3.05) 
+ (tumor size  0.15) 
– (ER/PR  1.15)
In this formula, tumor size is entered in centimeters, and
ER/PR is assigned “1” if positive (that is, ER or PR is posi-
tive) and “0” if both are negative. Scores ≥2.41 and <2.41 allo-
cate patients to a high- or low-risk category, with risks of
relapse of 65% and 11%, respectively. The differences in RFS
(P < .000001) and OS (P < .00005) were highly signiﬁcant
(Figure 7A). The model has 60% sensitivity, 90% speciﬁcity,
65% positive predictive value, 88% negative predictive value,
and 83% accuracy. This predictive model was subsequently
validated in an external set of 225 patients treated at Duke
University with STAMP-I and followed for a median of 46
months (range, 4-127 months) (Figure 7B).
The predictive value of the nodal ratio, probably supe-
rior to that of the absolute number of positive lymph nodes,
has been conﬁrmed in other retrospective analyses reported
at the ASCO 2000 Meeting [119,120].
Bitran et al. [121] reported a correlation between
Her-2/neu overexpression and risk of relapse in 25 patients
with ≥10 positive nodes after high-dose cyclophosphamide-
thiotepa. These results were conﬁrmed in a larger analysis
of 146 HRPBC patients treated with STAMP-I at the Uni-
versity of Colorado (Figure 8) [122].
Is HDCT Better Than Standard-Dose Chemotherapy
for HRPBC?
As with MBC, uncontrolled phase 2 trials in this setting
suggested an advantage for recipients of HDCT compared
to historical controls treated with standard chemotherapy.
This apparent improvement in outcome has been attributed
by some authors to a stage-migration phenomenon resulting
from extensive pre-HDCT staging and to patient-selection
bias [123,124]. In contrast, the comparison made by Gianni
et al. [105] between their 2 trials of HDCT and standard
chemotherapy using the same selection criteria and pre-
treatment staging tests argues against the relevance of these
hypotheses.
The ﬁrst results from small randomized phase 2 studies
were reported at the 1998 ASCO Meeting. In the trial by
Rodenhuis et al. [125], 81 patients received neoadjuvant
chemotherapy with FEC, surgery, and 1 postoperative cycle
of FEC. The patients were then randomized to HDCT with
cyclophosphamide-thiotepa-carboplatin or observation. All
patients received locoregional RT and tamoxifen after sys-
temic treatment. The high-dose arm had a 15% drop-out
Figure 7. Relapse-free survival curves of high-risk primary breast cancer patients treated at the Bone Marrow Transplant Programs at the University
of Colorado (A) (n = 176) and Duke University (B) (n = 225), stratiﬁed according to their predictive score. HDC indicates high-dose chemotherapy.
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rate. An intent-to-treat analysis did not show signiﬁcant dif-
ferences in DFS or OS between the 2 arms. A major prob-
lem with interpreting the results of this trial was the non-
standard staging procedure used to determine eligibility.
Patients in this study did not have a complete axillary node
dissection. Inclusion in this study was based on axillary level
III involvement, determined by an infraclavicular lymph-
node biopsy, and not based on the number of positive nodes.
Additionally, the study was sized with an 80% power to
detect a 30% absolute difference in outcome. It is worth
noting that this difference would have been much greater
than the overall impact of adjuvant chemotherapy for breast
cancer compared with no treatment at all.
Hortobagyi et al. [126] randomized 78 patients with ≥10
positive nodes after up-front surgery or ≥4 positive nodes
after preoperative chemotherapy to 8 cycles of FAC, fol-
lowed by 2 cycles of DICEP or no further therapy. Patients
in both arms received RT and tamoxifen upon completion
of chemotherapy. At a median follow-up of 53 (range 7-85)
months, DFS and OS were not significantly different
between both arms. Of note, this trial was prematurely
closed due to slow accrual. The DICEP regimen has been
proven to be nonmyeloablative [127,128] and is not consid-
ered HDCT by most experts.
Thus, neither of these 2 small studies contributes mean-
ingfully to our understanding of whether HRPBC patients
beneﬁt from HDCT. They were not phase 3 trials designed
to address this question and were not powered to detect
realistic differences between arms.
An answer as to what merit there is to HDCT over stan-
dard-dose CT in HRPBC will come from the well-designed,
adequately powered, randomized phase 3 studies, after sufﬁ-
cient follow-up. Most of such trials have already completed
accrual. The preliminary results of 2 of them, analyzed after
short follow-up, were ﬁrst reported at the 1999 ASCO Meet-
ing. In the Intergroup CALGB 9082 trial, Peters et al. [129]
enrolled patients with ≥10 positive nodes identiﬁed after a
standard axillary dissection. Eligible patients received 4
cycles of CAF and were randomized to high-dose STAMP-I
or to a single cycle of the same 3-drug combination at inter-
mediate doses with G-CSF support (Figure 2A). This study,
designed to detect a 14% difference in DFS at 5 years, ran-
domized a total of 785 patients, 394 to the STAMP-I and
391 to the intermediate-dose arm. Twenty patients who
relapsed on the intermediate-dose arm received subsequent
salvage HDCT. All patients were scheduled to receive
locoregional RT and, if hormone receptor–positive, tamox-
ifen for 5 years. Preliminary results were reported at a
median follow-up of 37 months and after the occurrence of
only 60% of the expected number of relapses. The relapse
rate in the high-dose arm (21.6%; 95% conﬁdence interval,
17.5-25.6%) was lower than in the intermediate-dose arm
(32.2%; 95% confidence interval, 27.6-36.9%), with
nonoverlapping conﬁdence intervals. This represents a 34%
relative reduction in the frequency of relapses. There were
29 toxic deaths (7.4%) in the HDCT arm, with centers
transplanting >50 patients tending to have lower treatment-
related mortality than those performing fewer transplanta-
tions. There were no toxic deaths in the control arm. The
RFS (68% versus 64%; P = .7) and OS (78% versus 80%;
P = .1) comparisons between the HDCT and control arms
were inconclusive. Whether the already signiﬁcantly fewer
relapses in the HDCT arm had not yet translated into an
improved outcome simply because of the short follow-up or
because they were compromised by an increase in toxic
deaths, as has been suggested [130], can only be determined
after adequate follow-up. Because the design of the study
called for a minimum follow-up of 5 years before its ﬁrst pre-
liminary analysis, its current results are clearly too immature
for any deﬁnitive conclusion.
A separate analysis showed that patients randomized to
the transplantation arm were less likely to initiate RT after
Figure 8. Relapse-free survival of 146 high-risk primary breast cancer patients treated at the University of Colorado Bone Marrow Transplant Pro-
gram according to Her-2/neu status. HDCT indicates high-dose chemotherapy.
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systemic therapy than patients allocated to the conventional
chemotherapy arm (78% versus 89%, P < .001) because of
the toxicity associated with STAMP-I [131].
A companion study compared quality of life after treat-
ment in 210 patients enrolled in the aforementioned trial
(106 in the STAMP-I arm and 104 in the control arm). There
were signiﬁcant differences in favor of the control arm at the
3-month timepoint, but quality-of-life scores were virtually
identical between arms at 1, 2, and 3 years [132].
A randomized trial from Scandinavia was also presented
at the 1999 ASCO Meeting [133]. This study targeted
HRPBC patients, deﬁned as having ≥8 involved nodes or ≥5
involved nodes with an ER-negative, high S-phase fraction
tumor. The investigators randomized 525 patients to 9
cycles of individually tailored dose-intensive FEC or to 3
cycles of conventional FEC, followed by HDCT with
STAMP-V. Doses in the tailored dose-intensive FEC arm
were escalated to as high as 120 mg/m2 of epirubicin and
1800 mg/m2 of cyclophosphamide, according to the blood
nadir counts of the preceding cycle. All patients in both
arms received RT and tamoxifen for 5 years. None of the
staging tests usually performed in HDCT clinical trials were
performed before randomization to exclude women with
metastatic disease. As has been pointed out [134], the
planned total dose in the tailored dose-intensive arm signiﬁ-
cantly exceeds that of the HDCT arm. At early median fol-
low-up of 23.7 months, there were no signiﬁcant differences
between the STAMP-V and the tailored FEC arm in relapse
rate, RFS, or OS. Despite the short follow-up, 8 cases of
secondary myelodysplastic syndrome/acute leukemia (3.2%)
had already been noticed in the tailored FEC arm. Two
patients in the STAMP-V arm (0.7%) died from acute regi-
men-related toxicity.
The early reporting of results from the CALGB and
Scandinavian studies at the 1999 ASCO Meeting, which was
considered premature by many investigators, may have led
many oncologists to conclude that HDCT lacked superior-
ity over standard-dose chemotherapy. Thus, patient referral
to HDCT clinical trials has dropped dramatically since
ASCO 1999, most notably to SWOG 9623 for stage II/III
patients with ≥4 positive nodes, the only randomized trial of
HDCT currently open in the United States. To complicate
the issue, the debunking of a fraudulent trial from South
Africa (also reported at ASCO 1999) that showed an appar-
ently clear beneﬁt for HDCT and its logical repercussion in
the media and public opinion further harmed accrual into
transplantation trials.
Although the enthusiastic acceptance in the early and
mid 1990s of HDCT seemed unreasonable to some breast
cancer experts because of the absence of phase 3 data, the
present “antitransplantation” opinion among many oncolo-
gists worldwide after the 1999 ASCO meeting appears
unjustiﬁed, because it is not supported by mature and con-
vincing results of randomized trials in either the metastatic
or the adjuvant setting. Rodenhuis et al. [135] recently
reported at the ASCO 2000 meeting the ﬁrst results of the
Dutch randomized trial, which accrued from 1992 to 1999 a
total of 885 patients with HRPBC. Of those, 570 had 4 to 9
positive nodes and 315 presented with ≥10 positive nodes
after surgery. Patients were randomized to receive 5 cycles
of FEC or 4 cycles of FEC followed by HDCT with CTCb
(cyclophosphamide 6000 mg/m2, thiotepa 480 mg/m2, and
carboplatin 1600 mg/m2), followed in both arms by chest
wall RT and tamoxifen. This trial has a 90% power to detect
a decrease in relapse hazard of 24%. None of the patients
randomized to the control arm received transplantation off
study, and 94% of the patients randomized to the HDCT
arm were actually transplanted. After a median follow-up of
3.5 years, only 200 of the 570 expected events have
occurred. There have been 4 treatment-related deaths in the
transplantation arm (1%). The analysis of the first 284
enrolled patients, followed for a median 4.5 years, shows
statistically signiﬁcant differences in favor of the transplan-
tation arm in DFS (77% versus 62%; P = .009) and OS
(89% versus 79%; P = .04). The transplantation arm has an
improved outcome both in the 4 to 9 and in the ≥10 positive
lymph node subgroups. Importantly, only after 2.5 to
3 years of follow-up did the DFS and OS curves of both
groups start to separate, which may help to interpret the
early results of other trials. In the early analysis of the whole
study population after a median follow-up of 3.5 years, dif-
ferences in DFS between the transplantation and the con-
trol arm are of borderline significance (72% versus 65%,
respectively; P = .05), but differences in OS have not yet
appeared (84% and 80%, respectively; P = .31).
The controversy about the efficacy of HDCT for
HRPBC remains far from settled. The available results of
3 phase 3 trials, still too preliminary for any conclusion,
have not appeared in peer-reviewed journals but as meeting
abstracts. We await the results of 10 other large randomized
trials in North America and Europe, many of which have
completed accrual and will be analyzed within the next year
(Table 4). It is critical to bear in mind that the ascertainment
of a potential beneﬁt of HDCT over standard-dose chemo-
therapy requires mature follow-up and that premature eval-
uation of randomized trials can be misleading. The Euro-
pean Parma study for aggressive non-Hodgkin’s lymphoma
illustrates this point. Preliminary analyses of this study were
negative [136,137], and only after the appropriate duration
of follow-up did statistically signiﬁcant differences become
apparent, with 5-year DFS rates of 46% and 12% for the
HDCT and control arms, respectively, at the time of the
deﬁnitive analysis [138].
PURGING OF STEM CELL GRAFTS
Peripheral blood progenitor cells (PBPCs) have
replaced bone marrow (BM) as the primary source of
hematopoietic progenitors for ASCT. Although tumor
burden may be lower in PBPC than in BM fractions [139],
breast cancer cells can be detected in PBPC fractions of
10% to 40% of MBC patients and of 5% to 20% of stage
II to III patients [140-144]. Detection of breast cancer cells
in the BM at the time of HDCT has been correlated with
an increased risk of relapse in HRPBC [145-147], but not
in MBC [148]. Most post-HDCT relapses in MBC
patients occur in sites of prior disease, suggesting an insuf-
ficient cytoreductive capacity of HDCT rather than a
direct effect from tumor cells contaminating the graft.
Thus, the clinical impact of procedures directed at purging
the graft of tumor cells will probably have to be deter-
mined in the adjuvant setting.
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Negative purging has been tested in patients with BM
metastases. Pharmacological purging achieved a mean 2.5-
log tumor-cell depletion, with a marked engraftment delay
[149]. Studies using immunomagnetic purging showed a
mean 3-log depletion of cancer cells, with no prolongation
of the engraftment times compared to historical controls
[150]. Both procedures combined resulted in a 4.5-log
tumor-cell depletion [151], at the expense of substantial
engraftment delays [152].
Positive selection targets the CD34 antigen, expressed
on 0.5% to 3% of normal BM cells and PBPCs, including
both the committed and, probably, the long-term reconsti-
tuting progenitor cells. The CD34 antigen does not appear
to be expressed on breast cancer cells [153]. The University
of Colorado Bone Marrow Transplant Program reported a
series of 155 breast cancer patients who received HDCT
and a BM or PBPC graft that was CD34– selected with the
Ceprate immunoadsorption device (CellPro, Bothell, WA)
[154]. CD34– selected stem cells effectively reconstituted
immediate and long-term hematopoiesis. An average 2-log
tumor-cell depletion was achieved. Patients receiving
CD34– selected PBPCs experienced neutrophil and platelet
recovery rates that were comparable to those of patients
who received unmanipulated grafts. Long-term follow-up
showed that the durability of engraftment, immune recon-
stitution, DFS, and OS were comparable to those of patients
receiving unmanipulated hematopoietic cell fractions (Uni-
versity of Colorado Bone Marrow Transplant Program,
unpublished data, 2000). A subsequent prospective random-
ized study demonstrated that breast cancer patients who
received HDCT with an autologous CD34– selected mar-
row graft had reduced marrow infusion-related toxicity and
comparable neutrophil engraftment times and immune
function recovery and, for those who received ≥1.2  106
CD34+ cells/kg, time to platelet engraftment comparable to
women who received unselected buffy coat fractions of mar-
row [155].
Cornetta et al. [156] recently reported the preliminary
results of a multicenter trial in 205 stage II to IV breast can-
cer patients who were randomized to receive CD34– selected
PBPC (using the Isolex 300/300i device) or an unselected
peripheral blood graft. There were no signiﬁcant differences
between the 2 groups in engraftment parameters or adverse
events. Times to relapse were not different between the
Table 4. Ongoing Randomized Trials in High-Risk Primary Breast Cancer*
Trial Target Target Size of 
(Principal Investigator) Population Target Population Control Arm High-Dose Arm Study Status
USA, CALGB ≥10 pos LN 874 CAF  4→ID CCB CAF  4→STAMP-I Accrual closed (5/98) 
(W.P. Peters) Preliminary analysis: 12/98†
USA, ECOG ≥10 pos LN 550 CAF  6 CAF  6→Cy/TT Accrual closed (8/98)
(M. Tallman) Planned analysis: 12/00
Australia, IBCSG ≥10 pos LN 340 AC  4→CMF  3 EC  3 Accrual closed
(R. Basser) Planned analysis: 2001
Scandinavian ≥7 pos LN 525 Tailored FEC  9 Standard FEC  3→STAMP-V Accrual closed (3/98)
(J. Bergh) Preliminary analysis: 12/98†
France, PEGASE 01 ≥7 pos LN 314 FEC  4 FEC  4→Cy/mitox/mel Accrual closed (12/98)
(H. Roché) Planned analysis: 12/00
Holland, NWAST ≥4 pos LN 885 FEC  5 FEC  4→Cy/TT/carbo Accrual closed (7/99)
(S. Rodenhuis) Preliminary analysis: 12/99†
UK, Anglo-Celtic ≥4 pos LN 604 A  4→CMF  8 A  4→Cy/TT Accrual closed (6/99)
(R. Leonard) Planned analysis: 12/00
Italy, INT 9009 ≥4 pos LN 300 E  3→CMF  6 HDST Accrual closed
(A.M. Gianni) Planned analysis: 8/00
USA, SWOG ≥4 pos LN 1000 Dose-dense AC  4→STAMP-I/STAMP-V
(S.I. Bearman) AAA→TTT→CCC Accruing
International, BCIRG ≥4 pos LN 460 TAC  6 TAC  4→Cy/mitox/vinorelbine Accruing
(J.M. Nabholtz)
Spain, SOLTI (Lluch) 4-9 pos LN 250 EC  4 EC  4→STAMP-V Accruing
Germany (Zander) ≥10 pos LN ? EC  4→CMF  3 EC  4→Cy/TT/mitox ?
Germany (Seeber) ≥10 pos LN ? EC  3→CMF  3 EC  4→Cy/carbo→TT/mitox ?
*High-dose regimens are presented in italic. CALGB indicates Cancer and Leukemia Group B; pos LN, positive lymph nodes; CAF, cyclophos-
phamide, adriamycin, and ﬂuorouracil; ID CCB, intermediate-dose cyclophosphamide, cisplatin, and BCNU; STAMP-I, cyclophosphamide, cis-
platin, and BCNU; ECOG, Eastern Cooperative Oncology Group; Cy, cyclophosphamide; TT, thiotepa; IBCSG, International Breast Cancer
Study Group; AC, adriamycin and cyclophosphamide; CMF, cyclophosphamide, methotrexate, and 5-ﬂuorouracil; EC, epirubicin and cyclophos-
phamide; FEC, ﬂuorouracil, epirubicin, and cyclophosphamide; STAMP-V, cyclophosphamide, thiotepa, and carboplatin; PEGASE, Programme
d’Étude de la Greffe Autologue dans les Cancers du Sein; mitox, mitoxantrone; mel, melphalan; NWAST, Netherlands Working Party on Auto-
transplantation in Solid Tumors; carbo, carboplatin; A, adriamycin; INT, Istituto Nazionale Tumori; E, epirubicin; HDST, high-dose sequential
therapy (cyclophosphamide→vincristine-methotrexate→thiotepa-melphalan); SWOG, Southwestern Oncology Group; AAA, adriamycin  3;
TTT, taxol  3; CCC, cyclophosphamide  3; BCIRG, Breast Cancer International Research Group; TAC, taxotere, adriamycin, and cyclophos-
phamide; SOLTI, Grupo Español de Intensiﬁcación de Tumores Sólidos.
†Preliminary analysis presented at an American Society of Clinical Oncology meeting.
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groups in the subset of stage III to B/IV patients (P = .65), but
those stage II/III-A patients who received a CD34– selected
graft had a signiﬁcantly longer time to relapse than those who
received an unselected graft (P = .04).
Because most patients still had detectable cancer cells
present in their stem cell grafts after CD34– selection, maxi-
mally effective purging may require a combination of posi-
tive- and negative-selection procedures. Preclinical studies
have demonstrated a larger magnitude of tumor-cell deple-
tion using a sequential combination rather than using a
simultaneous combination (averages 6.38-log and 4.29-log,
respectively) (University of Colorado Bone Marrow Trans-
plant Program, unpublished data, 2000). Patients receiving
PBPCs purged with simultaneous CD34– selection and
immunomagnetic purging experienced prompt and sus-
tained engraftment [157]. Sequential positive and negative
purging of PBPCs is presently under clinical evaluation. If it
does not produce engraftment delays, a randomized trial
will compare this approach to unmanipulated ASCT in
patients with ≥10 positive nodes receiving HDCT.
OTHER DIRECTIONS OF POTENTIAL IMPROVEMENT
Autologous hematopoietic cells may be manipulated in
vitro to improve treatment outcomes. It may be possible to
genetically modify hematopoietic stem and progenitor
cells—for instance, transductions with the multidrug resis-
tance gene MDR-1—to protect them from posttransplanta-
tion myelotoxic chemotherapy [158-161].
Different strategies are being evaluated to eradicate post-
transplantation minimal residual disease. Pilot trials at the
University of Pittsburgh [162] and the M.D. Anderson Cancer
Center [161] have shown the feasibility of posttransplantation
chemotherapy with adriamycin and paclitaxel, respectively.
The induction of autologous graft-versus-tumor effect with
cyclosporin and other cytokines has been tested [163-165].
Dendritic cells are the professional antigen-presenting
cells with the highest capacity to activate naive T cells and
initiate the immune response [166]. Dendritic cells can be
cultured from PBPCs using a combination of cytokines,
including granulocyte-macrophage colony-stimulating fac-
tor (GM-CSF) and interleukin-4, and subsequently pulsed
with a breast tumor–rejection antigen, such as MUC-1 in
breast cancer for use in the posttransplantation setting.
Achievement of CRs with HDCT may allow institution of
innovative therapies posttransplantation to prevent recur-
rence by such immunologic approaches or novel agents,
such as angiogenesis inhibitors. All new therapies will
require the scrutiny of controlled clinical trials.
Allogeneic marrow or blood stem cell transplantation
has been shown to confer an immune graft-versus-tumor
effect against hematologic malignancies. Ueno et al. [167]
from M.D. Anderson conducted a pilot study of this
approach in MBC and reported that a graft-versus-tumor
effect may occur in breast cancer patients receiving allo-
transplants from HLA-matched sibling donors. This obser-
vation needs to be confirmed in larger studies, and it is
unclear whether the potential beneﬁt will justify the addi-
tional risks of allogeneic transplantation.
A nonmyeloablative “mini-allotransplantation”
approach is under evaluation at several institutions, incorpo-
rating less intense preparative regimens with reduced toxic-
ity. This therapy can provide enough immunosuppression to
allow engraftment of allogeneic stem cells in patients with
lymphoid malignancies [168,169]. The goal of a mini-allo-
transplantation in breast cancer is to provide a graft-versus-
tumor effect with reduced toxicity.
Radioimmunotherapy, using [131I]-labeled anti-CD20, is
highly active in B-cell lymphoma [170-172]. Its dose-limit-
ing toxicity is myelosuppression. Stem cell–supported deliv-
ery of the radiometal Yttrium-90, conjugated to humanized
BrE-3 monoclonal antibody and directed to an epitope of
the human milk-fat globulin (MUC-1), is presently being
explored for MBC. Preliminary results of a phase 1 PBPC-
supported trial suggest the feasibility of a substantial dose
escalation of this isotope, well above its MTD without stem
cell support [173].
The Her2/neu oncogene is overexpressed in 25% to
30% of breast cancer patients [174]. Humanized monoclo-
nal antibodies directed against the Her2/neu receptor
(trastuzumab [Herceptin]) have shown activity in Her2/neu-
positive tumors [175,176] and in vitro synergy with cis-
platin, carboplatin, docetaxel, etoposide, and thiotepa [177].
Clinical studies of the combination of this antibody with cis-
platin [178], adriamycin-cyclophosphamide [179], or pacli-
taxel [178] showed an improved outcome compared with the
same chemotherapy alone. Current trials are testing the
combination of trastuzumab with HDCT.
CONCLUSIONS
HDCT constitutes an approach to improve therapeutic
results in breast cancer that is based on a solid rationale.
Although results from phase 2 studies are encouraging, an
answer to the important question of its relative merit over
standard chemotherapy will come only from the mature
results of randomized phase 3 studies, most of which are still
underway, either in the accrual phase or with enrollment
completed. Such data will be forthcoming within the next
few years. In the meantime, it is imperative that research
continues to improve HDCT regimens and integrate them
with novel strategies possessing different and potentially
complementary mechanisms of action.
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